Chemotherapy regimen for recurrent uterine leiomyosarcoma

Uterine leiomyosarcoma is a rare gynecological malignancy, the limited literature indicated that doxorubicin alone or gemcitabine/docetaxel combination is the preferred chemotherapy regimen. Given the rarity of the disease and the lack of high-level clinical evidence, there is no consensus on the best treatment.

We report a case of a patient with uterine leiomyosarcoma who recurred after adjustment treatment with doxorubicin, gemcitabine, docetaxel, and anlotinib; and required a new chemotherapy regimen.

The follow-up chemotherapy regimen was doxorubicin-liposome 40 mg/m² on one day in combination with dacarbazine 250 mg/m² on one to five days of intravenous infusion every 21 days. We monitored adverse effects during chemotherapy and the process was smooth.

It is important to comprehensively consider the patient's condition, and fully consider the efficacy, dosage, and adverse reactions of the chemotherapy regimen to determine the appropriate plan, in order to achieve the best therapeutic benefits for patients.